Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Neutral” Rating from Wedbush

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating reiterated by analysts at Wedbush in a report issued on Tuesday,RTT News reports. They currently have a $4.00 price target on the stock. Wedbush’s price objective suggests a potential upside of 193.26% from the company’s previous close.

ZNTL has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Leerink Partners reissued a “market perform” rating and set a $2.00 target price on shares of Zentalis Pharmaceuticals in a research note on Tuesday. HC Wainwright raised Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.20.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL traded up $0.04 during trading hours on Tuesday, hitting $1.36. The stock had a trading volume of 156,695 shares, compared to its average volume of 1,097,360. The firm has a market cap of $98.40 million, a P/E ratio of -0.60 and a beta of 1.87. The company’s fifty day simple moving average is $1.55 and its 200 day simple moving average is $1.45. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Acadian Asset Management LLC boosted its holdings in Zentalis Pharmaceuticals by 150.6% in the 1st quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock valued at $4,244,000 after purchasing an additional 1,606,802 shares during the period. Nuveen LLC acquired a new position in shares of Zentalis Pharmaceuticals during the first quarter valued at about $807,000. Tybourne Capital Management HK Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after acquiring an additional 516,666 shares during the period. GSA Capital Partners LLP boosted its position in shares of Zentalis Pharmaceuticals by 275.9% during the 1st quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock valued at $862,000 after acquiring an additional 397,805 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Zentalis Pharmaceuticals in the first quarter valued at about $81,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.